Sclerosis multiplex (SM): vizsgálatok itt: Kína

In Kína 29 Also abroad 558

22 of 29 trials · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.

1. fázisTaking people
A Study of IMS001 in Patients With Multiple Sclerosis
Where
Chengdu
Életkor
18 év to 65 év
People
4
Run by
Zhuhai Hengqin ImStem Biotechnology Co., Ltd.
See details and how to joinNCT07935031
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Where
Beijing, Changchun, Chongqing, Guangzhou, Hangzhou, Hohhot, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wenzhou, Wuhan, Xianyang, Yinchuan, Zhengzhou, Zunyi
Életkor
18 év to 65 év
People
1275 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07225504
3. fázisTaking people
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Where
Beijing, Chengdu, Dongguan, Guangzhou, Jiazhuang, Shenyang
Életkor
18 év to 60 év
People
160 worldwide
Run by
Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00
2. fázisTaking people
A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis
Where
Wuhan
Életkor
18 év to 65 év
People
100
Run by
Chuan Qin
See details and how to joinNCT07827716
Korai 1. fázisNot yet taking people in Kína
A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Relapsing/Refractory Multiple Sclerosis
Where
Wuhan
Életkor
18 év to 65 év
People
12
Run by
Daishi Tian
See details and how to joinNCT07748637
2. fázisTaking people
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
Where
Beijing
Életkor
18 év to 65 év
People
30
Run by
Guangzhou Lupeng Pharmaceutical Company LTD.
See details and how to joinNCT07776743
1/2. fázisNot yet taking people in Kína
Phase Ib/II Study of SYS6020 in Relapsing/Refractory Multiple Sclerosis
Where
Wuhan
Életkor
18 év to 65 év
People
25
Run by
Tongji Hospital
See details and how to joinNCT07756268
1. fázisTaking people
Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis
Where
Xi'an
Életkor
18 év to 75 év
People
9
Run by
Xijing Hospital
See details and how to joinNCT07587125
1. fázisNot yet taking people in Kína
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Where
Qingdao
Életkor
18 év to 70 év
People
18
Run by
The Affiliated Hospital of Qingdao University
See details and how to joinNCT07676266
Korai 1. fázisTaking people
This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple Sclerosis
Where
Hubei
Életkor
18 év and over
People
9
Run by
Daishi Tian
See details and how to joinNCT07303790
No phaseNot yet taking people in Kína
A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
Where
Beijing
Életkor
18 év to 75 év
People
75
Run by
Beijing GoBroad Hospital
See details and how to joinNCT07593911
Korai 1. fázisTaking people
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Where
Wuhan
Életkor
18 év to 70 év
People
36
Run by
Tongji Hospital
See details and how to joinNCT07337785
1. fázisTaking people
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Where
Wuhan
Életkor
18 év to 75 év
People
6
Run by
Tongji Hospital
See details and how to joinNCT07526493
1. fázisNot yet taking people in Kína
A Study on the Safety and Tolerability of Universal STAR-T Cell Therapy for Multiple Sclerosis.
Where
Wuhan
Életkor
18 év to 65 év
People
24
Run by
Daishi Tian
See details and how to joinNCT07523100
Korai 1. fázisNot yet taking people in Kína
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases
Where
Tianjin
Életkor
18 év and over
People
15
Run by
Tianjin Huanhu Hospital
See details and how to joinNCT07392528
Korai 1. fázisTaking people
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
Where
Tianjin
Életkor
18 év and over
People
12
Run by
Tianjin Huanhu Hospital
See details and how to joinNCT06939166
No phaseTaking people
Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases
Where
Beijing
Életkor
18 év to 60 év
People
128
Run by
Xuanwu Hospital, Beijing
See details and how to joinNCT07087873
1. fázisTaking people
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Where
Shanghai
Életkor
18 év to 70 év
People
30
Run by
RenJi Hospital
See details and how to joinNCT06249438
No phaseTaking people
Effectiveness of Personalized Alternating Current Stimulation for Treating Cognitive Impairment in CNS Demyelination Patients
Where
Beijing
Életkor
18 év to 65 év
People
85
Run by
Xuanwu Hospital, Beijing
See details and how to joinNCT06968039
Korai 1. fázisNot yet taking people in Kína
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
Where
Beijing
Életkor
18 év to 75 év
People
25
Run by
Xuanwu Hospital, Beijing
See details and how to joinNCT06485232
Korai 1. fázisTaking people
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
Where
Wuhan
Életkor
18 év to 75 év
People
36
Run by
Tongji Hospital
See details and how to joinNCT04561557
No phaseTaking people
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
Where
Wuhan
Életkor
18 év and over
People
250
Run by
Tongji Hospital
See details and how to joinNCT06474520